EGELİ, Ü. Et Al. 2016. miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation.. Pancreas , vol.45, no.9 , 1294-302.

EGELİ, Ü., Tezcan, G., ÇEÇENER, G., TUNCA, B., Sevinc, E. D., KAYA, E., ... Ak, S.(2016). miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation.. Pancreas , vol.45, no.9, 1294-302.

EGELİ, ÜNAL Et Al. "miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation.," Pancreas , vol.45, no.9, 1294-302, 2016

EGELİ, ÜNAL Et Al. "miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation.." Pancreas , vol.45, no.9, pp.1294-302, 2016

EGELİ, Ü. Et Al. (2016) . "miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation.." Pancreas , vol.45, no.9, pp.1294-302.

@article{article, author={ÜNAL EGELİ Et Al. }, title={miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation.}, journal={Pancreas}, year=2016, pages={1294-302} }